CG ONCOLOGY, INC.

Andere talen CG Oncology, Inc.

Aandelen

CGON

US1569441009

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
29,98 ^USD	-3,20%		+5,19%	0,00%

14/05	CG ONCOLOGY, INC. : Goldman Sachs herziet advies naar Kopen	ZM
09/05	CG Oncology, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates	09/05
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	06/05
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	03/05
CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin	03/05
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024	26/04
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024	24/04
PACS Group to raise $450 mln in US IPO at over $3 bln valuation	11/04
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting	28/03
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P TMI Index	18/03
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer	27/02
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut	09/02
Fractyl Health valued at $654.6 mln in tepid debut	02/02
Fractyl Health prices US IPO below range to raise $110 mln	02/02
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares	31/01
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	30/01
Fractyl Health targets up to $762 mln valuation in US IPO	29/01
CG Oncology, Inc.(NasdaqGS:CGON) added to NASDAQ Composite Index	26/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

De beste beleggingen van morgen voortaan makkelijk te vinden!

Mijn winst optimaliseren

fermer